Uncharacterized 12.7 kDa protein in transposon Tn903 Antibody

What is the structure and function of transposon Tn903?

Transposon Tn903 is a bacterial mobile genetic element that carries kanamycin resistance. Its structure and function have been extensively characterized:

Structure:

• Tn903 consists of a unique central region of approximately 1000 base pairs bounded by a pair of 1050-base-pair inverted repeat sequences .

• Each inverted repeat contains two Pvu II endonuclease cleavage sites separated by 520 base pairs .

• The 18 base pairs at each end of the transposon are identical and inverted relative to one another, which is characteristic of insertion sequences .

Genetic Components:

• It encodes an aminoglycoside 3'-phosphotransferase type I (APH(3')-I), which confers resistance to kanamycin and related compounds .

• It potentially encodes a 307-amino-acid polypeptide believed to function as a transposase, essential for the mobility of the transposon .

• The Uncharacterized 12.7 kDa protein is also encoded within this transposon .

Functional Characteristics:

• Derivatives of Tn903 lacking the 520-base-pair fragments from both inverted repeats cannot transpose, whereas those lacking just one fragment remain transposition-proficient .

• A single inverted repeat from Tn903 can independently transpose and has been designated as IS903 .

• Mutations created by inserting DNA fragments at sites within the intact repeat of Tn903 affect transposability, suggesting that the transposon encodes a functional transposase .

How is this protein related to kanamycin resistance?

The relationship between the Uncharacterized 12.7 kDa protein and kanamycin resistance is indirect. Within Tn903, kanamycin resistance is primarily conferred by the aminoglycoside 3'-phosphotransferase (APH(3')-I) enzyme , which is distinct from the Uncharacterized 12.7 kDa protein.

The APH(3')-I enzyme functions by:

• Phosphorylating the 3'-hydroxyl group of kanamycin and related aminoglycosides

• Preventing these antibiotics from binding to the bacterial ribosome

• Thereby conferring resistance to kanamycin, neomycin, and structurally related compounds

The Uncharacterized 12.7 kDa protein likely serves a different function within the transposon, potentially related to:

• Transposition mechanisms

• Structural support for the transposon

• Regulation of transposon mobility

• Interaction with host factors

This distinction is important for researchers investigating the multiple functions encoded by transposable elements and highlights the complex organization of these mobile genetic elements.

What expression systems are available for producing this protein?

Several expression systems are available for producing the Uncharacterized 12.7 kDa protein, each with distinct advantages depending on research needs:

According to commercial sources, the protein can be expressed with various tags, which can be determined during the manufacturing process based on research requirements . The protein is typically provided as a lyophilized powder and should be reconstituted in deionized sterile water to a concentration of 0.1-1.0 mg/mL .

For long-term storage, addition of 5-50% glycerol and storage at -20°C/-80°C is recommended . E. coli-based expression appears to be the most common and cost-effective system for basic research applications.

What experimental approaches should be used to characterize the function of this protein?

Characterizing the function of the Uncharacterized 12.7 kDa protein requires a multi-faceted approach:

Genetic Approaches:

• Gene Knockout Studies: Create knockout strains lacking the gene encoding the 12.7 kDa protein to observe phenotypic changes in transposition frequency or transposon stability. The fur::Tn903 mutation approach used in some studies provides a model for similar insertional inactivation techniques .

• Complementation Assays: Reintroduce the gene into knockout strains to restore function and confirm the gene's role.

• Site-Directed Mutagenesis: Create specific mutations in the protein's sequence to identify critical functional residues.

Biochemical Approaches:

• Protein-Protein Interaction Studies: Use techniques such as co-immunoprecipitation, yeast two-hybrid assays, or proximity labeling to identify interaction partners, particularly with the transposase component of Tn903.

• DNA-Binding Assays: Employ electrophoretic mobility shift assays (EMSA) or DNase footprinting to determine if the protein interacts with specific DNA sequences within the transposon.

• Enzymatic Activity Assays: Investigate potential enzymatic functions related to transposition.

Structural Approaches:

• X-ray Crystallography or Cryo-EM: Determine the three-dimensional structure to provide insights into function.

• NMR Spectroscopy: Reveal dynamic aspects of protein structure and potential binding sites.

• Computational Modeling: Use homology modeling or molecular dynamics simulations to predict structural features.

Systems Biology Approaches:

• Transcriptomics: Compare gene expression profiles between wild-type and knockout strains, similar to the microarray analyses performed with fur::Tn903 strains .

• Proteomics: Use mass spectrometry to identify changes in the proteome caused by the presence or absence of the protein.

A recent application of the HyperMu<R6K+ori/KAN-1> transposon containing the aph gene from Tn903 demonstrated its utility in functional metagenomics studies , suggesting similar approaches could be adapted to study the 12.7 kDa protein's function in various contexts.

How can researchers distinguish between this protein and the aminoglycoside phosphotransferase (APH) in experimental settings?

Distinguishing between the Uncharacterized 12.7 kDa protein and the aminoglycoside phosphotransferase (APH) in Tn903 requires specific experimental approaches:

Molecular Weight Discrimination:

• The Uncharacterized 12.7 kDa protein is significantly smaller than APH(3')-I (which is approximately 29 kDa)

• SDS-PAGE analysis can easily separate these proteins based on size differences

Functional Assays:

• Enzymatic Activity: APH(3')-I has a specific kinase activity that can be measured through:

  • Phosphorylation assays using radiolabeled ATP

  • Coupled enzyme assays that monitor ADP production

  • Resistance phenotype testing

• The 12.7 kDa protein lacks this enzymatic activity

Specific Antibodies:

• Generate antibodies that specifically recognize unique epitopes of each protein

• Use these in Western blotting, immunoprecipitation, or immunofluorescence studies

• Epitope mapping can confirm antibody specificity

Genetic Approaches:

• Create constructs with different tags for each protein

• Express them separately in different expression systems

• Generate specific knockout strains for each gene

Mass Spectrometry:

• Tryptic digestion produces unique peptide fingerprints for each protein

• Targeted proteomics approaches can specifically detect and quantify each protein

• Selected/Multiple Reaction Monitoring (SRM/MRM) can be developed for high-specificity detection

The aminoglycoside 3'-phosphotransferase gene (APH(3')-I) from Tn903 has been extensively used as a selection marker in various genetic systems, including for eukaryotic expression where it confers resistance to G418 (geneticin) . This distinct functional property provides another means of distinguishing it from the Uncharacterized 12.7 kDa protein.

What is the potential role of this protein in transposition mechanisms?

While the specific role of the Uncharacterized 12.7 kDa protein in transposition mechanisms remains to be fully elucidated, several hypotheses can be proposed based on our understanding of transposon biology:

Potential Roles:

• Regulatory Function: The protein might regulate transposition activity by controlling the expression or activity of the transposase enzyme encoded by Tn903.

• Structural Component: It may serve as part of the nucleoprotein complex (transpososome) that forms during transposition, providing structural support or specificity.

• Host Interaction Mediator: The protein could interact with host factors to facilitate integration into new genomic sites or to evade host defense mechanisms.

• DNA Binding and Recognition: It might assist in recognizing specific DNA sequences at the target site or within the transposon itself.

Experimental Evidence from Tn903 Studies:

Research on Tn903 has shown that:

• Mutations in the inverted repeat sequences affect transposition efficiency , suggesting that proteins interacting with these regions (potentially including the 12.7 kDa protein) are important for function.

• The 18 base pairs at each end of the inverted repeats are identical and inverted relative to one another , potentially serving as binding sites for transposition proteins.

• Derivatives lacking certain segments of the transposon show altered transposition capabilities , indicating complex protein-DNA interactions during transposition.

Studies of the related kanamycin resistance transposon Tn5 have provided valuable insights into mechanisms and control of transposition , which might be applicable to understanding the function of proteins in Tn903.

The precise role of this protein would contribute to our broader knowledge of transposition mechanisms and could potentially inform strategies to control the spread of antibiotic resistance genes carried by transposons.

How does the evolutionary history of this protein compare to other transposon-encoded proteins?

The evolutionary history of the Uncharacterized 12.7 kDa protein in transposon Tn903 must be considered in the context of transposon evolution and horizontal gene transfer:

Relationship to Other Transposons:

• Tn903 belongs to a family of kanamycin resistance transposons that includes others like Tn5

• The kanamycin resistance determinant in Tn903 (APH(3')-I) is distinct from that in Tn5 (APH(3')-II) , suggesting independent evolutionary origins or significant divergence

Conservation Analysis:

• The 12.7 kDa protein appears to be specific to Tn903 and closely related elements

• Sequence analysis could reveal potential homologs in other transposons, but specific information about such homology is limited in the current literature

Mobile Genetic Element Context:

• Tn903 has been found in various plasmids including R-factors , suggesting its mobility across different genetic contexts

• The transposon contains inverted repeat sequences (IS903) that may have their own evolutionary history

Horizontal Gene Transfer:

• The presence of Tn903 across different bacterial species indicates horizontal gene transfer events

• The ability of laboratory-engineered elements containing Tn903 components to enter environmental samples demonstrates the ongoing potential for transfer

Environmental Impact:

• Recent evidence shows that engineered elements containing the aph gene from Tn903 have been detected in environmental samples

• This suggests that transposon components can persist and become part of the environmental resistome through horizontal gene transfer

Research Implications:

• Studying the evolutionary relationships between transposon-encoded proteins can provide insights into the dissemination of antibiotic resistance

• Comparative genomics approaches can help trace the origins and spread of transposon components

• Understanding these relationships has implications for predicting and potentially controlling the spread of antibiotic resistance genes

The "recycling" of genes from Tn903 into different scaffolds and their subsequent release into the environment represents an iatrogenic contribution to the evolution of mobile resistance determinants , highlighting the importance of understanding the evolutionary dynamics of these elements.

What are the best methods for detecting this protein in bacterial samples?

Detecting the Uncharacterized 12.7 kDa protein in bacterial samples requires selecting appropriate methods based on sensitivity, specificity, and available resources:

Antibody-Based Methods:

• Western Blotting:

  • Extract proteins from bacterial cultures using appropriate lysis buffers

  • Separate proteins by SDS-PAGE (15-20% gels recommended for small proteins)

  • Transfer to PVDF or nitrocellulose membrane

  • Probe with specific antibodies against the 12.7 kDa protein

  • Detection limit: Approximately 0.1-1 ng of protein

  • Applications: Confirming expression, comparing levels between strains

• Enzyme-Linked Immunosorbent Assay (ELISA):

  • Develop sandwich ELISA using purified antibodies

  • Quantify against a standard curve of purified recombinant protein

  • Higher throughput than Western blotting

  • Applications: Quantitative analysis across multiple samples

Mass Spectrometry-Based Methods:

• Targeted Proteomics (SRM/MRM):

  • Design assay targeting unique peptides from the protein sequence

  • Extract proteins and perform tryptic digestion

  • Use triple quadrupole MS to monitor specific transitions

  • Quantify using isotope-labeled peptide standards

  • Applications: Highly specific detection even in complex samples

Genetic Fusion Approaches:

• Epitope Tagging:

  • Create genetic constructs with common epitope tags (FLAG, HA, Myc)

  • Express in bacterial systems

  • Detect using commercially available antibodies against the tag

  • Applications: When specific antibodies against the native protein are unavailable

• Fluorescent Protein Fusions:

  • Create genetic fusions with fluorescent proteins

  • Visualize using fluorescence microscopy

  • Applications: Localization studies, real-time monitoring

Sample Preparation Considerations:

When working with samples where the protein might be present in low abundance, immunoprecipitation followed by Western blotting or mass spectrometry can improve detection sensitivity. For all antibody-based methods, validation using samples from knockout strains is essential to confirm specificity.

How can researchers optimize expression and purification of this protein?

Optimizing expression and purification of the Uncharacterized 12.7 kDa protein requires careful consideration of expression systems, culture conditions, and purification strategies:

Expression System Selection:

Based on commercial product information, E. coli expression of this protein can achieve >85% purity by SDS-PAGE , making it suitable for most research applications.

Expression Optimization in E. coli:

• Vector Design:

  • Use pET, pBAD, or pTrc vectors with appropriate promoters

  • Include fusion tags to aid purification (His6, GST, MBP)

  • Consider codon optimization for E. coli expression

• Culture Conditions:

  • Test multiple temperatures (16°C, 25°C, 37°C)

  • Vary IPTG concentration (0.1-1.0 mM)

  • Test different media (LB, TB, auto-induction)

  • Optimize induction time (3-24 hours)

Purification Strategy:

• Initial Extraction:

  • Lyse cells using sonication, French press, or commercial lysis reagents

  • Test buffers with different pH values (typically pH 7.0-8.0)

  • Include protease inhibitors (PMSF, EDTA, or commercial cocktails)

• Affinity Chromatography:

  • For His-tagged protein: Ni-NTA or TALON resin

  • For GST-tagged protein: Glutathione Sepharose

  • For MBP-tagged protein: Amylose resin

  • Optimize imidazole concentration for His-tag elution

• Secondary Purification:

  • Size exclusion chromatography (Superdex 75 or equivalent)

  • Ion exchange chromatography based on theoretical pI

  • Tag removal using specific proteases if necessary

Storage Considerations:

According to commercial protocols , this protein should be:

• Reconstituted in deionized sterile water to 0.1-1.0 mg/mL

• Supplemented with 5-50% glycerol for long-term storage

• Stored at -20°C/-80°C in aliquots to avoid freeze-thaw cycles

Quality Control:

• Verify purity by SDS-PAGE (target >85%)

• Confirm identity by Western blotting or mass spectrometry

• Assess activity through functional assays if available

• Check for proper folding using circular dichroism

For researchers requiring specific modifications or tags, custom expression services are available that can optimize conditions for this particular protein .

What are the critical considerations when developing antibodies against this protein?

Developing effective antibodies against the Uncharacterized 12.7 kDa protein requires careful planning and consideration of several critical factors:

Antigen Design:

• Full-length vs. Peptide Immunogens:

  • Full-length protein: Provides all potential epitopes but may include conserved regions

  • Synthetic peptides: Allows targeting of unique regions but may not represent native conformation

  • Recombinant fragments: Compromise between the two approaches

• Epitope Selection for Peptide Antibodies:

  • Target regions with high antigenicity and surface exposure

  • Avoid hydrophobic regions or transmembrane domains

  • Select peptides from unique regions not conserved in related proteins

  • Ideal peptide length: 10-20 amino acids

• Carrier Protein Conjugation:

  • Small proteins (<15 kDa) benefit from carrier conjugation

  • Common carriers: KLH, BSA, or OVA

  • Ensure different carriers for immunization and screening to avoid carrier antibodies

Antibody Production Strategies:

• Polyclonal Antibodies:

  • Advantages: Multiple epitope recognition, higher sensitivity, faster production

  • Host animals: Rabbit, goat, or chicken (for phylogenetically distant hosts)

  • Immunization schedule: Initial immunization followed by 3-4 boosts over 2-3 months

  • Expected titer: >10,000 for good antibody production

• Monoclonal Antibodies:

  • Advantages: Single epitope specificity, consistent performance, unlimited supply

  • Production: Hybridoma technology or recombinant antibody display methods

  • Screening methods: ELISA against recombinant protein and Western blotting

  • Species considerations: Rabbit monoclonal antibodies typically have 10-100 times higher affinity than mouse antibodies

• Recombinant Antibody Approaches:

  • Phage display technology for antibody discovery

  • Selection strategies: panning against purified protein or whole cells

  • Advantages: No animals required, rapid selection, easier engineering

Validation Requirements:

• Specificity Tests:

  • Western blotting against purified protein and cell lysates

  • Testing in knockout/knockdown samples as negative controls

  • Cross-reactivity assessment with related proteins

  • Immunoprecipitation followed by mass spectrometry confirmation

• Application-Specific Validation:

  • For WB: Test different reducing/non-reducing conditions

  • For IP: Optimize buffer conditions and antibody concentrations

  • For IHC/ICC: Test different fixation methods

  • For ELISA: Determine optimal coating conditions and detection limits

Storage and Handling:

• Proper aliquoting to avoid freeze-thaw cycles

• Addition of preservatives for liquid antibodies

• Appropriate storage at -20°C or -80°C

• Validation of antibody stability over time

Phage display technology, as described in the search results , offers particular advantages for developing antibodies against poorly characterized proteins, as it allows screening of large antibody libraries against the target protein to identify high-affinity binders.

How can CRISPR/Cas9 technology be applied to study this protein?

CRISPR/Cas9 technology provides powerful tools for studying the Uncharacterized 12.7 kDa protein in transposon Tn903. Here's a comprehensive approach:

Gene Knockout Studies:

• CRISPR-Mediated Gene Deletion:

  • Design sgRNAs targeting the gene encoding the 12.7 kDa protein

  • Use CRISPR-Cas9 to introduce double-strand breaks

  • Allow non-homologous end joining (NHEJ) to create frameshift mutations

  • Alternatively, provide a donor template for homology-directed repair (HDR)

  • Validate knockout by sequencing and Western blotting

  • Analyze phenotypic effects on:

    • Transposition frequency

    • Transposon stability

    • Bacterial growth characteristics

• Scarless Gene Deletion:

  • Design HDR templates with homology arms flanking the target gene

  • Replace the gene with selectable markers or create clean deletions

  • Similar to the approach used to create fur::Tn903 mutants described in the literature

Gene Editing for Functional Analysis:

• Point Mutations:

  • Create specific amino acid substitutions to test functional hypotheses

  • Target conserved residues or predicted functional domains

  • Use HDR with donor DNA containing desired mutations

  • Compare effects of different mutations on protein function

• Domain Swapping:

  • Replace domains with corresponding regions from related proteins

  • Create chimeric constructs to determine domain-specific functions

  • Analyze the resulting phenotypes to understand domain contributions

Protein Tagging for Localization and Interaction Studies:

• Endogenous Tagging:

  • Add fluorescent protein or epitope tags to the endogenous gene

  • Create C- or N-terminal fusions at the genomic locus

  • Use for subcellular localization or purification studies

  • Similar to how M45 epitope tagging has been used for other proteins

• Pull-Down Studies:

  • Tag the protein with affinity tags (His, FLAG, etc.)

  • Perform pull-down experiments to identify interaction partners

  • Validate interactions using reciprocal tagging approaches

Expression Modulation:

• CRISPRi (CRISPR Interference):

  • Use catalytically inactive Cas9 (dCas9) to block transcription

  • Target the promoter region to reduce expression

  • Create a tunable knockdown rather than complete knockout

  • Useful for studying dosage effects

• CRISPRa (CRISPR Activation):

  • Use dCas9 fused to transcriptional activators

  • Increase expression of the endogenous gene

  • Study effects of overexpression on transposition

Experimental Design Considerations: